Review
Published on 10 Mar 2023
LSD1 inhibition modulates transcription factor networks in myeloid malignancies
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1149754
- 9,179 views
- 9 citations
Type at least 3 characters
2,056 articles
articles
Brief Research Report
Published on 10 Mar 2023
Comparison of first-line treatment with bendamustine plus rituximab versus R-CHOP for patients with follicular lymphoma grade 3A: Results of a retrospective study from the Fondazione Italiana Linfomi
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1120967
- 6,699 views
- 6 citations
Editorial
Published on 09 Mar 2023
Editorial: Advances in the treatment of chronic myeloid leukemia
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1166588
- 3,445 views
- 7 citations
Original Research
Published on 09 Mar 2023
A novel conditioning regimen of chidamide, cladribine, gemcitabine, and busulfan in the autologous stem cell transplantation of aggressive T-cell lymphoma
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1143556
- 2,931 views
- 3 citations
Editorial
Published on 08 Mar 2023
Editorial: Hybrid or mixed myelodyplastic/myeloproliferative disorders: Current trends in diagnosis and treatment
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1166163
- 1,693 views
- 1 citation
Original Research
Published on 07 Mar 2023
Replication stress increases mitochondrial metabolism and mitophagy in FANCD2 deficient fetal liver hematopoietic stem cells
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1108430
- 3,722 views
- 5 citations
Brief Research Report
Published on 07 Mar 2023
Thromboembolic events in patients with paroxysmal nocturnal hemoglobinuria (PNH): Real world data of a Greek nationwide multicenter retrospective study
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1128994
- 7,528 views
- 23 citations
Perspective
Published on 07 Mar 2023
Treatment selection for patients with relapsed or refractory follicular lymphoma
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1120358
- 8,410 views
- 5 citations
Original Research
Published on 06 Mar 2023
Bone marrow CD34+ molecular chimerism as an early predictor of relapse after allogeneic stem cell transplantation in patients with acute myeloid leukemia
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1133418
- 3,511 views
- 6 citations
Review
Published on 03 Mar 2023
Advances in the treatment of Hodgkin lymphoma: Current and future approaches
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1067289
- 16,219 views
- 20 citations
Case Report
Published on 02 Mar 2023
Case report: Ruxolitinib plus dexamethasone as first-line therapy in haemophagocytic lymphohistiocytosis
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1054175
- 3,028 views
- 6 citations
Editorial
Published on 28 Feb 2023
Editorial: Advances in the treatment of Hodgkin lymphoma
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1164081
- 2,227 views
Original Research
Published on 27 Feb 2023
TRIM37 interacts with PTEN to promote the growth of human T-cell acute lymphocytic leukemia cells through regulating PI3K/AKT pathway
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2022.1016725
- 4,098 views
- 5 citations
Original Research
Published on 27 Feb 2023
Primary refractory plasmablastic lymphoma: A precision oncology approach
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1129405
- 4,469 views
- 8 citations
Original Research
Published on 27 Feb 2023
Serological and cellular response to mRNA-SARS-CoV2 vaccine in patients with hematological lymphoid malignancies: Results of the study “Cervax”
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1133348
- 3,268 views
- 2 citations
Original Research
Published on 27 Feb 2023
Hereditary predisposition to malignant myeloid hemopathies: Caution in use of saliva and guideline based on our experience
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1120829
- 2,528 views
- 2 citations
Editorial
Published on 24 Feb 2023
Editorial: Advances in the understanding of pathogenesis, diagnosis, and therapy of light chain amyloidosis
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1163490
- 1,577 views
- 1 citation
Original Research
Published on 23 Feb 2023
Integrating copy number data of 64 iAMP21 BCP-ALL patients narrows the common region of amplification to 1.57 Mb
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1128560
- 3,391 views
- 6 citations
Original Research
Published on 23 Feb 2023
Developing mRNA signatures as a novel prognostic biomarker predicting high risk multiple myeloma
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1105196
- 4,249 views
- 1 citation
Perspective
Published on 23 Feb 2023
Benefits of switching from intravenous to subcutaneous daratumumab: Perspectives from UK healthcare providers
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1063144
- 10,398 views
- 18 citations
Review
Published on 22 Feb 2023
The evolving use of measurable residual disease in chronic lymphocytic leukemia clinical trials
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1130617
- 6,114 views
- 10 citations
Review
Published on 22 Feb 2023
Immunophenotypic measurable residual disease monitoring in adult acute lymphoblastic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1047554
- 3,089 views
- 2 citations
Original Research
Published on 21 Feb 2023
Prognostic value of lipid profile in adult hemophagocytic lymphohistiocytosis
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1083088
- 3,650 views
- 9 citations
Editorial
Published on 21 Feb 2023
Editorial: The role of the bone marrow microenvironment in multiple myeloma evolution and therapy
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1157555
- 2,975 views
- 5 citations